ReviewReproductive medicine and biology
Potential Role of CREM in Diabetes-Associated Testicular Dysfunction: Current Evidence and Future Perspectives.
Review in Reproductive medicine and biology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Single-cell transcriptomics reveals heterogeneity and immune microenvironment in lymphatic metastasis of head and neck squamous cell carcinoma.Genes and immunity · 2026Article
- Cardiovascular Dysfunction in Polycystic Ovary Syndrome: Mitochondrial and Inflammatory Mechanisms.BioMed research international · 2026Review
- Antidiabetic agents and male fertility: unraveling the impact of glucose-lowering therapies on sperm quality in diabetic males-a narrative review.Translational andrology and urology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Type 2 diabetes mellitus (T2D) is a growing metabolic disorder affecting all age groups and is linked to testiculopathy, a key contributor to male infertility. Testiculopathy disrupts spermatogenesis and the sperm microenvironment, with the cyclic adenosine monophosphate (cAMP) response element modulator (CREM) playing a pivotal role in testicular function. Understanding the interplay between T2D and CREM dysregulation is essential for developing targeted therapies for diabetic testicular dysfunction. Methods: A systematic review of PubMed, Web of Science, Scopus, and Google Scholar was conducted to identify peer-reviewed studies, both preclinical and clinical, that explored CREM's role in diabetes-induced testicular dysfunction. Extracted data focused on CREM expression, oxidative stress, apoptosis, and spermatogenic impairment in diabetic models. Main Findings: Research from studies on diabetic patients and animal models highlights the detrimental effects of diabetes on the reproductive system, including hypothalamic-pituitary-testicular (HPT) axis dysregulation. CREM regulates spermatogenic gene expression, influenced by luteinizing hormone (LH), follicle-stimulating hormone (FSH), and cAMP signaling. Conclusion: CREM has a therapeutic role in maintaining testicular function, and its disruption may contribute to testiculopathy in T2D, highlighting its potential therapeutic target for preserving male fertility in diabetic patients. Further research is needed to explore its molecular mechanisms and therapeutic implications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.